From Surf Wiki (app.surf) — the open knowledge base
1-Methyltryptophan
1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO or INDO ). It is a chiral compound that can exist as both D- and L-enantiomers.
The L-isomer (L-1MT) inhibits IDO weakly but also serves as an enzyme substrate.
The D-isomer (D-1MT) does not inhibit IDO at all, but it can inhibit the IDO-related enzyme IDO2 and restore mTOR signaling in cells starved of tryptophan due to IDO activity. D-1MT is also known as indoximod and it was in clinical trials for cancer treatment, such as for advanced melanoma, in 2017.
A U.S. patent covering salt and prodrug formulations of indoximod was issued to NewLink Genetics on August 15, 2017, providing exclusivity until at least 2036.
References
References
- (1991). "1-Methyl-{{small". Archives of Biochemistry and Biophysics.
- (2007). "Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound {{small". Cancer Research.
- (2012). "IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by {{small". OncoImmunology.
- [http://www.onclive.com/publications/oncology-live/2017/vol-18-no-16/ido-inhibitors-emerging-as-new-players-on-checkpoint-blockade-scene?p=2 IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene. Aug 2017]
- "NewLink Genetics".
- (April 9, 2018). "NewLink Genetics Annual Report (Form 10-K)".
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about 1-Methyltryptophan — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report